Effect of Long-term Psoriasis on Patients' Life - CORONATE
NCT ID: NCT05555953
Last Updated: 2024-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
543 participants
OBSERVATIONAL
2023-01-26
2024-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Approximately 550 adult participants with moderate to severe plaque psoriasis will be enrolled in approximately 15 dermatology centers in Italy.
Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study. The duration of this study is up to 22 months.
There is no additional burden for participants in this study. Participants will attend regular visits during the course of the study at a hospital or clinic.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
NCT01276639
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
NCT01163253
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
NCT01241591
Clinical Assessment and Psychosocial Impact of Psoriasis
NCT01964443
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
NCT01309737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase-1
The draft CORONATE questionnaire will be administered to participants to create the final version of the questionnaire.
No interventions assigned to this group
Phase-2
The questionnaire created in Phase 1 will be administered to a new group of participants for validation. All partners who are in a relationship with the participants since at least 3 years will be asked to participate in the study for the comparison between participants' and partners' perspectives on the impact of long-term psoriasis on participants' life.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult partner in relationship with the participant since at least 3 years(Part 2 only).
Exclusion Criteria
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZIENDA USL TOSCANA CENTRO - Piero Palagi /ID# 245569
Florence, Firenze, Italy
Ospedale San Martino /ID# 245641
Genoa, Genova, Italy
Presidio Ospedaliero San Salvatore /ID# 245618
L’Aquila, L Aquila, Italy
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 245116
Rome, Roma, Italy
Policlinico Agostino Gemelli /ID# 245570
Rome, Roma, Italy
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Sant'Anna /ID# 246438
Turin, Torino, Italy
Azienda Ospedaliero Universitaria delle Marche /ID# 245117
Ancona, , Italy
A.O.U. Consorziale Policlinico di Bari /ID# 245276
Bari, , Italy
ASST degli Spedali Civili di Brescia /ID# 245694
Brescia, , Italy
Ospedale Villa Scassi /ID# 245445
Genova, , Italy
Azienda Ospedaliera Universitaria Gaetano Martino /ID# 245507
Messina, , Italy
Azienda Ospedale-Universita Padova /ID# 245115
Padua, , Italy
Azienda Ospedaliero-Universitaria di Parma /ID# 244950
Parma, , Italy
Ospedale Infermi Di Rimini /ID# 245199
Rimini, , Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento /ID# 245119
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H23-093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.